Drug research

ARC-520

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus InfectionNCT02604212	Arrowhead Pharmaceuticals	Phase 2	Terminated	2016-12Actual
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)NCT02577029	Arrowhead Pharmaceuticals	Phase 2	Terminated	2016-12Actual
Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusNCT02452528	Arrowhead Pharmaceuticals	Phase 2	Terminated	2016-12Actual
A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) InfectionNCT02065336	Arrowhead Pharmaceuticals	Phase 2	Terminated	2017-01Actual

Arrowhead PharmaceuticalsTerminatedPrimary completion: 2016-12 · Actual

Trial details

Arrowhead PharmaceuticalsTerminatedPrimary completion: 2016-12 · Actual

Trial details

Arrowhead PharmaceuticalsTerminatedPrimary completion: 2016-12 · Actual

Trial details

Arrowhead PharmaceuticalsTerminatedPrimary completion: 2017-01 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.